NeoDynamics AB hereby publishes the annual report for the financial year 2021. The annual report is attached to this press release and is available on the company's website: https://www.neodynamics.com/sv-se/rapporter
For further information, please contact
Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail firstname.lastname@example.org
CFO Aaron Wong, phone +46 73 597 2011 or e-mail email@example.com
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients.